Global Leukemia Therapeutics Market Research Report 2019

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Leukemia Therapeutics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Leukemia Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Gleevec
  • 1.4.3 Sprycel
  • 1.4.4 Tasigna
  • 1.4.5 Clolar
  • 1.4.6 Others
• 1.5 Market by Application
  • 1.5.1 Global Leukemia Therapeutics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospital
  • 1.5.3 Clinic
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Leukemia Therapeutics Market Perspective (2015-2026)
• 2.2 Global Leukemia Therapeutics Growth Trends by Regions
  • 2.2.1 Leukemia Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Leukemia Therapeutics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Leukemia Therapeutics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Leukemia Therapeutics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Leukemia Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Leukemia Therapeutics Players by Market Size
  • 3.1.1 Global Top Leukemia Therapeutics Players by Revenue (2015-2020)
  • 3.1.2 Global Leukemia Therapeutics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Leukemia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Leukemia Therapeutics Market Concentration Ratio
  • 3.2.1 Global Leukemia Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Leukemia Therapeutics Revenue in 2019
• 3.3 Leukemia Therapeutics Key Players Head office and Area Served
• 3.4 Key Players Leukemia Therapeutics Product Solution and Service
• 3.5 Date of Enter into Leukemia Therapeutics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Leukemia Therapeutics Historic Market Size by Type (2015-2020)
• 4.2 Global Leukemia Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Leukemia Therapeutics Market Size by Application (2015-2020)
• 5.2 Global Leukemia Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Leukemia Therapeutics Market Size (2015-2020)
• 6.2 Leukemia Therapeutics Key Players in North America (2019-2020)
• 6.3 North America Leukemia Therapeutics Market Size by Type (2015-2020)
• 6.4 North America Leukemia Therapeutics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Leukemia Therapeutics Market Size (2015-2020)
• 7.2 Leukemia Therapeutics Key Players in Europe (2019-2020)
• 7.3 Europe Leukemia Therapeutics Market Size by Type (2015-2020)
• 7.4 Europe Leukemia Therapeutics Market Size by Application (2015-2020)

8 China

• 8.1 China Leukemia Therapeutics Market Size (2015-2020)
• 8.2 Leukemia Therapeutics Key Players in China (2019-2020)
• 8.3 China Leukemia Therapeutics Market Size by Type (2015-2020)
• 8.4 China Leukemia Therapeutics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Leukemia Therapeutics Market Size (2015-2020)
• 9.2 Leukemia Therapeutics Key Players in Japan (2019-2020)
• 9.3 Japan Leukemia Therapeutics Market Size by Type (2015-2020)
• 9.4 Japan Leukemia Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Leukemia Therapeutics Market Size (2015-2020)
• 10.2 Leukemia Therapeutics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Leukemia Therapeutics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Leukemia Therapeutics Market Size by Application (2015-2020)

11 India

• 11.1 India Leukemia Therapeutics Market Size (2015-2020)
• 11.2 Leukemia Therapeutics Key Players in India (2019-2020)
• 11.3 India Leukemia Therapeutics Market Size by Type (2015-2020)
• 11.4 India Leukemia Therapeutics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Leukemia Therapeutics Market Size (2015-2020)
• 12.2 Leukemia Therapeutics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Leukemia Therapeutics Market Size by Type (2015-2020)
• 12.4 Central & South America Leukemia Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Roche
  • 13.1.1 Roche Company Details
  • 13.1.2 Roche Business Overview
  • 13.1.3 Roche Leukemia Therapeutics Introduction
  • 13.1.4 Roche Revenue in Leukemia Therapeutics Business (2015-2020))
  • 13.1.5 Roche Recent Development
• 13.2 GlaxoSmithKline
  • 13.2.1 GlaxoSmithKline Company Details
  • 13.2.2 GlaxoSmithKline Business Overview
  • 13.2.3 GlaxoSmithKline Leukemia Therapeutics Introduction
  • 13.2.4 GlaxoSmithKline Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.2.5 GlaxoSmithKline Recent Development
• 13.3 Novartis
  • 13.3.1 Novartis Company Details
  • 13.3.2 Novartis Business Overview
  • 13.3.3 Novartis Leukemia Therapeutics Introduction
  • 13.3.4 Novartis Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.3.5 Novartis Recent Development
• 13.4 Bristol-Myers Squibb
  • 13.4.1 Bristol-Myers Squibb Company Details
  • 13.4.2 Bristol-Myers Squibb Business Overview
  • 13.4.3 Bristol-Myers Squibb Leukemia Therapeutics Introduction
  • 13.4.4 Bristol-Myers Squibb Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.4.5 Bristol-Myers Squibb Recent Development
• 13.5 Eisai
  • 13.5.1 Eisai Company Details
  • 13.5.2 Eisai Business Overview
  • 13.5.3 Eisai Leukemia Therapeutics Introduction
  • 13.5.4 Eisai Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.5.5 Eisai Recent Development
• 13.6 Biogen Idec
  • 13.6.1 Biogen Idec Company Details
  • 13.6.2 Biogen Idec Business Overview
  • 13.6.3 Biogen Idec Leukemia Therapeutics Introduction
  • 13.6.4 Biogen Idec Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.6.5 Biogen Idec Recent Development
• 13.7 ERYtech Pharma
  • 13.7.1 ERYtech Pharma Company Details
  • 13.7.2 ERYtech Pharma Business Overview
  • 13.7.3 ERYtech Pharma Leukemia Therapeutics Introduction
  • 13.7.4 ERYtech Pharma Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.7.5 ERYtech Pharma Recent Development
• 13.8 Celgene
  • 13.8.1 Celgene Company Details
  • 13.8.2 Celgene Business Overview
  • 13.8.3 Celgene Leukemia Therapeutics Introduction
  • 13.8.4 Celgene Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.8.5 Celgene Recent Development
• 13.9 Genmab
  • 13.9.1 Genmab Company Details
  • 13.9.2 Genmab Business Overview
  • 13.9.3 Genmab Leukemia Therapeutics Introduction
  • 13.9.4 Genmab Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.9.5 Genmab Recent Development
• 13.10 Cephalon
  • 13.10.1 Cephalon Company Details
  • 13.10.2 Cephalon Business Overview
  • 13.10.3 Cephalon Leukemia Therapeutics Introduction
  • 13.10.4 Cephalon Revenue in Leukemia Therapeutics Business (2015-2020)
  • 13.10.5 Cephalon Recent Development
• 13.11 Clavis Pharma
  • 10.11.1 Clavis Pharma Company Details
  • 10.11.2 Clavis Pharma Business Overview
  • 10.11.3 Clavis Pharma Leukemia Therapeutics Introduction
  • 10.11.4 Clavis Pharma Revenue in Leukemia Therapeutics Business (2015-2020)
  • 10.11.5 Clavis Pharma Recent Development
• 13.12 Pfizer
  • 10.12.1 Pfizer Company Details
  • 10.12.2 Pfizer Business Overview
  • 10.12.3 Pfizer Leukemia Therapeutics Introduction
  • 10.12.4 Pfizer Revenue in Leukemia Therapeutics Business (2015-2020)
  • 10.12.5 Pfizer Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer